- Conditions
- HIV Infections
- Interventions
- Varicella Virus Vaccine (Live)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Months to 8 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 25
- States / cities
- Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Zostavax vaccine
- Drug
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Herpes Zoster, HIV Infections
- Interventions
- ZOSTAVAX, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- HIV Infections, Chickenpox
- Interventions
- Varicella Virus Vaccine (Live)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 22
- States / cities
- Long Beach, California • Los Angeles, California • Torrance, California + 13 more
- Conditions
- Immunosenescence, Shingles
- Interventions
- Varicella Zoster Virus Vaccine (Zostavax)
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster Vaccine GSK1437173A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
- Conditions
- Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Herpes Zoster
- Interventions
- Herpes zoster vaccine GSK1437173A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 19 Months
- Enrollment
- 950 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
- Conditions
- Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
- Interventions
- Varicella Zoster Vaccine, Placebo Injection
- Biological · Other
- Lead sponsor
- Kevin Winthrop
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 5
- States / cities
- Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
- Interventions
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 15 Months
- Enrollment
- 852 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 365 Days
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
- Conditions
- Kidney Transplant Recipients
- Interventions
- Varivax®
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
- Conditions
- Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Zoster Vaccine Recombinant, Adjuvanted
- Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
- Interventions
- Herpes Zoster (HZ) Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more
- Conditions
- Osteosarcoma, Neuroblastoma
- Interventions
- GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
- Genetic · Biological · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2034
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Herpes Zoster
- Interventions
- Live attenuated herpes zoster vaccine, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
- Conditions
- Herpes Zoster, Postherpetic Neuralgia
- Interventions
- Varicella-zoster vaccine, Placebo
- Biological
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 60 Years and older
- Enrollment
- 38,456 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
- Conditions
- Achalasia
- Interventions
- ValACYclovir 1000 MG, Shingrix
- Drug · Biological
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
- Conditions
- Hepatitis C
- Interventions
- Zoster vaccine live
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 50 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Herpes Zoster
- Interventions
- Zostavax™
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California